1,473 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Acquired by US Bancorp DE

US Bancorp DE bought a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,473 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors have also made changes to their positions in KNSA. Geode Capital Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 2.0% during the 4th quarter. Geode Capital Management LLC now owns 492,630 shares of the company’s stock valued at $9,744,000 after purchasing an additional 9,654 shares during the last quarter. Wells Fargo & Company MN increased its position in Kiniksa Pharmaceuticals International by 54.7% during the 4th quarter. Wells Fargo & Company MN now owns 21,102 shares of the company’s stock valued at $417,000 after buying an additional 7,463 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the fourth quarter valued at about $3,955,000. Barclays PLC raised its stake in Kiniksa Pharmaceuticals International by 11.2% in the fourth quarter. Barclays PLC now owns 71,896 shares of the company’s stock valued at $1,423,000 after buying an additional 7,267 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Kiniksa Pharmaceuticals International by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company’s stock worth $15,262,000 after acquiring an additional 29,300 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, insider Ross Moat sold 27,594 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the transaction, the insider directly owned 9,415 shares of the company’s stock, valued at $273,223.30. The trade was a 74.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sanj K. Patel sold 62,116 shares of the business’s stock in a transaction on Wednesday, May 28th. The shares were sold at an average price of $27.33, for a total transaction of $1,697,630.28. Following the completion of the transaction, the chief executive officer owned 96,674 shares of the company’s stock, valued at approximately $2,642,100.42. This represents a 39.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 679,686 shares of company stock valued at $21,274,787 in the last 90 days. 53.48% of the stock is currently owned by corporate insiders.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA opened at $33.21 on Thursday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $34.55. The company has a market capitalization of $2.46 billion, a PE ratio of 830.46 and a beta of 0.14. The company has a fifty day moving average of $29.55 and a 200 day moving average of $25.29.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently commented on KNSA shares. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an “overweight” rating in a report on Wednesday, July 9th. Finally, Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Buy” and a consensus price target of $41.17.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.